Dendreon Corp (DNDN)

0.06
0.00 6.02
NASDAQ : Health Care
Prev Close 0.06
Open 0.06
Day Low/High 0.06 / 0.06
52 Wk Low/High 0.04 / 3.46
Volume 1.37M
Avg Volume 5.11M
Exchange NASDAQ
Shares Outstanding 158.72M
Market Cap 20.16M
EPS -1.95
P/E Ratio N/A
Div & Yield N.A. (N.A)
Dendreon To Host Conference Call On August 8 To Announce Second Quarter Financial Results

Dendreon To Host Conference Call On August 8 To Announce Second Quarter Financial Results

July 15, 2013-- Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Thursday, August 8, 2013, at 4:30 p.

Insider Trading Alert - Cepheid And 4 Others Traded By Insiders

Insider Trading Alert - Cepheid And 4 Others Traded By Insiders

Stocks with insider trader activity include CPHD, BYI, DNDN, AKAM and FDS

Insider Trading Alert - Dendreon And 4 Others Traded By Insiders

Insider Trading Alert - Dendreon And 4 Others Traded By Insiders

Stocks with insider trader activity include DNDN, BK, TIVO, YUM and GTAT

DNDN July 12th Options Begin Trading

DNDN July 12th Options Begin Trading

Investors in Dendreon Corp saw new options become available today, for the July 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new July 12th contracts and identified one put and one call contract of particular interest.

Dendreon Receives Positive Opinion For PROVENGE® In The European Union

Dendreon Receives Positive Opinion For PROVENGE® In The European Union

June 28, 2013--Dendreon Corporation (Nasdaq: DNDN) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that ...

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.

10 Most-Shorted Biotech Stocks of 2013

10 Most-Shorted Biotech Stocks of 2013

A lot of investors are betting these 10 biotechs stocks are going to fail. The most-shorted stock may surprise you.

Interesting DNDN Put And Call For June 7th

Interesting DNDN Put And Call For June 7th

Investors in Dendreon Corp saw new options begin trading today, for the June 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new June 7th contracts and identified one put and one call contract of particular interest.

Commit To Buy Dendreon At $2, Earn 26.5%

Commit To Buy Dendreon At $2, Earn 26.5%

Investors eyeing a purchase of Dendreon Corp shares, but tentative about paying the going market price of $3.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $2 strike, which has a bid at the time of this writing of 53 cents.

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

A Dendreon Shareholder Voices His Frustration at Incompetent Directors

A Dendreon Shareholder Voices His Frustration at Incompetent Directors

Dendreon investor Brad Loncar is tweeting from today's Dendreon annual shareholder meeting.

Oversold Conditions For Dendreon (DNDN)

Oversold Conditions For Dendreon (DNDN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

Cramer's 'Mad Money' Recap: It's Time to Pause

Cramer's 'Mad Money' Recap: It's Time to Pause

With the negatives coming into focus and the positives still only possibilities, Cramer said investors need to get cautious.

Dendreon Announces Securities Class Action Settlement

Dendreon Announces Securities Class Action Settlement

Dendreon Corporation (Nasdaq:DNDN) today announced that it has reached an agreement in principle to settle the securities class action litigation pending against it in the United States District Court for the Western...

Dendreon Announces Webcast Presentation At ROTH Conference

Dendreon Announces Webcast Presentation At ROTH Conference

March 12, 2013—Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the 25 th Annual ROTH Conference in Laguna Niguel, California, on March 18, 2013, at 11:00 a.

Shocker! Sell-Sider Admits Dendreon Buy Rating Was Mistake

Shocker! Sell-Sider Admits Dendreon Buy Rating Was Mistake

ISI Group's Mark Schoenebaum offers refreshing mea culpa on Dendreon bullishness.

Why Expect More Price Swings From These 4 Biotechs

Why Expect More Price Swings From These 4 Biotechs

Crish Lau, Kapitall Contributor  Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]

Dendreon Announces Fourth Quarter And 2012 Year End Results

Dendreon Announces Fourth Quarter And 2012 Year End Results

Dendreon Corporation (Nasdaq: DNDN) today reported results for the fourth quarter and full year ended December 31, 2012.

New PROVENGE® (sipuleucel-T) Data To Be Presented At 2013 American Society Of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

New PROVENGE® (sipuleucel-T) Data To Be Presented At 2013 American Society Of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

February 13, 2013--Dendreon Corporation (NASDAQ: DNDN) today announced that results from several ongoing or completed studies investigating the utility of PROVENGE ® (sipuleucel-T) in the treatment of advanced...

5 Stocks Showing Major Breakouts

5 Stocks Showing Major Breakouts

Once a stock trends to a new high, or takes out a prior overhead resistance point, then it's free to find new buyers and momentum players that can ultimately push the stock significantly higher.

Dendreon To Host Conference Call On February 25 To Announce Fourth Quarter And Full Year 2012 Financial Results And Webcast Presentations At Upcoming Conferences

Dendreon To Host Conference Call On February 25 To Announce Fourth Quarter And Full Year 2012 Financial Results And Webcast Presentations At Upcoming Conferences

Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 25, 2012, at 9:00 a.

Dendreon Corp (DNDN): Today's Featured Drugs Winner

Dendreon Corp (DNDN): Today's Featured Drugs Winner

Dendreon was a winner within the drugs industry, rising 8 cents (1.3%) to $6.33 on light volume.

Seeking Alpha Author Used Multiple Aliases to Tout Biotech Stocks

Seeking Alpha Author Used Multiple Aliases to Tout Biotech Stocks

The five articles written under three different aliases all promoted Galena Biopharma.

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Cramer's 6 Stocks in 60 Seconds: CMI CVX PG BUD PRGO DNDN (Update 1)

Cramer's 6 Stocks in 60 Seconds: CMI CVX PG BUD PRGO DNDN (Update 1)

Cramer is bullish on Dendreon and Anheuser-Busch Inbev and would love to see Procter& Gamble split itself.

Not a Healthy Bet

Despite Deerfield Management's interest in this biotech name, we would not recommend it.

Arena Pharmaceuticals And 6 More Stocks To Watch

Arena Pharmaceuticals And 6 More Stocks To Watch

Rising short-interest indicates bearishness for the company is building up by investors. Between November 30 2012 and December 14, short-selling [...]

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

Live, interactive coverage of the biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

Dendreon Announces Preliminary Fourth Quarter 2012 Revenues

Dendreon Announces Preliminary Fourth Quarter 2012 Revenues

Dendreon Corporation (NASDAQ: DNDN) today announced preliminary revenues for the fourth quarter ended December 31, 2012.